


US\$N 10/091,232

OFFICIAL
CT 2666 NPClaim Amendments

1. (currently amended) A compound of Formula (I)



or a pharmaceutically acceptable salt or solvate thereof

wherein

 A^1 and A^2 are each independently C_{1-4} alkylene or a bond; A^3 is C_{1-4} alkylene or C_{1-4} alkylidene; A^4 is C_{1-4} alkylene or a bond and is attached to X, X^1 or X^2 ;X, X^1 , X^2 and X^3 are independently C or CH;J is C_{1-4} alkyl;

p is 0 or 1;

 R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;

USSN 10/091,232

OFFICIAL
CT 2666 NP

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholine, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny and tetrahydroisoquinoliny, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano;

or wherein A¹-R¹ and A²-R² together with the nitrogen to which they are attached form pyrrolyl, pyrroliny, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazoliny, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholine, adamantyl, indolyl, isoindolyl, indoliny, quinoliny, dihydroquinoliny, tetrahydroquinoliny, isoquinoliny, dihydroisoquinoliny or tetrahydroisoquinoliny and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl;

R³ is H or C₁₋₄alkyl;

m is 0 or 1;

R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro or C₁₋₃perfluoroalkyl;

wherein said R⁴ or R⁵ may be independently attached to X, X¹, X² or X³;

n is 0 or 1;

G is N, O or S;

G¹ is N or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

USSN 10/091,232

OFFICIAL
CT 2666 NP

both R^4 and R^5 are not attached to the same of said X , X^1 , X^2 or X^3 ;

~~if G is O or S, then m is 0;~~

if G is N, then m is 1;

if R^1 is $-N(H)C(O)OC_{1-4}alkyl$, or $C_{1-4}alkyl-N(H)C(O)O-$ ~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is $C_{2-4}alkylene$;~~

if R^2 is $-N(H)C(O)OC_{1-4}alkyl$, or $C_{1-4}alkyl-N(H)C(O)O-$ ~~or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is $C_{2-4}alkylene$;~~

if R^1 is $N(H)C(O)O-C_{1-4}alkyl$ or $C_{1-4}alkyl-N(H)C(O)O-$ ~~or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}alkyl$, $C_{1-4}alkoxy$ or cyano,~~
then R^2 is H or $C_{1-3}alkyl$;

if R^2 is $-N(H)C(O)O-C_{1-4}alkyl$, or $C_{1-4}alkyl-N(H)C(O)O-$ ~~or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and~~

USSN 10/091,232

OFFICIAL
CT 2666 NP

~~tetrahydroquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄ alkyl, C₁₋₄ alkoxy or cyano, then R¹ is H or C₁₋₃ alkyl;~~

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C;

~~if R⁴ is F and is attached to X and if A³ is methylene, then A¹-R¹ and A²-R² together with the nitrogen to which they are attached is not N-methyl piperazinyl; and~~

~~if R⁴ is F and is attached to X and if A³ is methylene, then A¹-R¹ and A²-R² together with the nitrogen to which they are attached is not tetrahydroquinolinyl.~~

2. (original) A compound according to claim 1 wherein p is 0.
3. (original) A compound according to claim 1 wherein G is N and G¹ is CH.
4. (previously canceled)
5. (previously canceled)
6. (original) A compound according to claim 1 wherein A¹ is a bond, R¹ is methyl, A² is a bond and R² is methyl.
7. (original) A compound according to claim 1 wherein R³ is H and m is 1.
8. (previously canceled)
9. (original) A compound according to claim 1 wherein R⁴ is hydrogen.
10. (previously canceled)
11. (original) A compound according to claim 1 wherein R⁴ is cyano.
12. (previously canceled)
13. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to

USSN 10/091,232

OFFICIAL
CT 2666 NP

which it is attached has an absolute configuration of S; and wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.

14. (original) A compound according to claim 1 wherein A³ is C₁₋₄alkylene.
15. (previously canceled)
16. (original) A compound according to claim 1 wherein A³ is methylene.
17. (original) A compound according to claim 1 wherein wherein A⁴ is a bond.
18. (previously canceled)
19. (original) A compound according to claim 1 wherein A⁴ is attached X¹.
20. (previously canceled)
21. (original) A compound according to claim 1 wherein R⁴ is attached X.
22. (original) A compound according to claim 1 wherein A¹ is a bond, A² is a bond, R¹ is methyl and R² is methyl.
23. (previously canceled)
24. (previously canceled)
25. (previously canceled)
26. (previously canceled)
27. (original) A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-C₁₋₄alkyl.
28. (original) A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, or -N(H)C(O)O-C₁₋₄alkyl.
29. (original) A compound according to claim 1 wherein R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, or -O-phenyl.
30. (canceled)
31. (previously canceled)
32. (previously canceled)
33. (previously canceled)
34. (previously canceled)
35. (previously canceled)
36. (previously canceled)
37. (previously canceled)

USSN 10/091,232

OFFICIAL
CT 2666 NP

38. (previously canceled)

39. (previously canceled)

40. (currently amended) A compound according to claim 1 wherein

 A^1 and A^2 are each independently C_{1-4} alkylene or a bond; A^3 is C_{1-4} alkylene; A^4 is a bond and is attached to X or X^1 ; R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl or -
 $N(H)C(O)O-C_{1-4}$ alkyl;said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and
optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo;~~or are independently selected from the group of heterocyclic moieties
consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl,
morpholine, adamantyl, indolyl, tetrahydroquinoliny and
tetrahydroisoquinoliny;~~~~or wherein A^1 , R^1 and A^3 , R^3 together with the nitrogen to which they are
attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholine,
adamantyl, tetrahydroquinoliny or tetrahydroisoquinoliny and are
optionally substituted with benzyl;~~ R^3 is H or C_{1-4} alkyl;

m is 0 or 1;

 R^4 is cyano or halo and is attached to X or X^1 ;

n is 0;

X and X^1 are each C; X^2 and X^3 are each CH;

G is N, O or S;

 G^1 is N or CH;

USSN 10/091,232

OFFICIAL
CT 2666 NP

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

~~if G is O or S; then m is 0;~~

if G is N, then m is 1;

if R^1 is $-N(H)C(O)OC_{1-4}$ alkyl or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is C_{2-4} alkylene;

if R^2 is $-N(H)C(O)OC_{1-4}$ alkyl or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is C_{2-4} alkylene;

if R^1 is $-N(H)C(O)O-C_{1-4}$ alkyl or said heterocyclic moiety, then R^2 is H or C_{1-3} alkyl;

if R^2 is $-N(H)C(O)O-C_{1-4}$ alkyl or said heterocyclic moiety, then R^1 is H or C_{1-3} alkyl;

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not N-methyl-piperazinyl; and~~

~~if R^4 is F and is attached to X and if A^3 is methylene, then A^1-R^1 and A^2-R^2 together with the nitrogen to which they are attached is not tetrahydroquinoliny.~~

41. (currently amended) *Trans*-2-[5-Cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)cyclopropane; *Trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]cyclopropane; *Trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-benzylaminomethyl]-cyclopropane; (1*S*,2*S*)-*trans*-1-(*N,N*-dimethylaminomethyl)-2-[5-fluoroindol-3-yl]-cyclopropane; (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[*N,N*-methyl-2-

USSN 10/091,232

OFFICIAL
CT 2666 NP

amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-1-(N-Benzylaminomethyl)-2-[5-cyanoindol-3-yl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-3-phenylpropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-indolyl)ethylaminomethyl]-cyclopropane; ~~*trans*-1-(4-Benzyl-piperidin-1-ylmethyl)-2-[5-cyanoindol-3-yl]-cyclopropane;~~ *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-dipropylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-methyl-phenylethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-phenylethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(2-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(3-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-(4-methoxyphenyl)ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N-2-phenoxy-ethylamino]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[pyrrolidin-1-yl-methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(propyl carbamoyl)ethylamino methyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(isopropylcarbamoyl)ethylaminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(methylcarbamoyl)propyl aminomethyl]-cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-[N,N-ethyl-2-amino(ethylcarbamoyl)propylaminomethyl]-cyclopropane; *Cis*-2-[5-Cyanoindol-3-yl]-1-(N,N-dimethyl aminomethyl)cyclopropane; *trans*-2-[5-Cyanoindol-3-yl]-1-(N-methylaminomethyl)cyclopropane; (1*S*,2*S*)-*trans*-2-[5-Cyanoindol-3-yl]-1-(N-methylaminomethyl)cyclopropane; *trans*-3-[2-(1-Dimethylamino-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile; *trans*-3-[2-(1-Pyrrolidin-1-yl-ethyl)-cyclopropyl]-1H-indole-5-carbonitrile; (-)*Cis*-2-[5-Cyanoindol-3-yl]-1-(N,N-dimethylaminomethyl)cyclopropane; 5-(2-Dimethylaminomethyl-cyclopropyl)-1H-indole-3-carbonitrile; [2-(5,6-Difluoro-1H-indol-3-yl)-cyclopropylmethyl]-dimethyl-amine; *Trans*-2-[5-cyanoindol-3-yl]-1-(3-(N-methylamino)propyl)cyclopropane; S,S-*Trans*-2-[5-Cyanoindol-3-yl]-1-(trimethylammoniummethyl)cyclopropane trifluoroacetate; S,S-*trans*-2-[5-cyano-1-methylindol-3-yl]-1-(N,N-dimethylamino)-cyclopropane; S,S-*trans*-2-[5-cyano-1-ethylindol-

USSN 10/091,232

OFFICIAL
CT 2666 NP

3-yl]-1-(*N,N*-dimethylamino)-cyclopropane; or 6-(2-Dimethylaminomethyl-cyclopropyl)-1*H*-indole-3-carbonitrile or pharmaceutically acceptable salts or solvates thereof.

42. (original) A pharmaceutically acceptable formulation comprising a compound according to claim 1.
43. (previously canceled)
44. (previously canceled)
45. (previously canceled)
46. (previously canceled)
47. (previously canceled)
48. (previously canceled)
49. (re-presented - formerly claim 8) A compound according to claim 1 wherein R^4 and R^5 are halo.
50. (re-presented - formerly claim 10) A compound according to claim 1 wherein R^4 is fluoro.
51. (re-presented - formerly claim 12) A compound according to claim 1 wherein R^4 and R^5 are each fluoro.
52. (re-presented - formerly claim 15) A compound according to claim 1 wherein A^3 is C_{1-4} alkylidene.
53. (re-presented - formerly claim 18) A compound according to claim 1 wherein A^4 is methylene.
54. (re-presented - formerly claim 20) A compound according to claim 1 wherein R^4 is attached X.
55. (re-presented - formerly claim 31) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.
56. (re-presented - formerly claim 32) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is N(H)C(O)O- C_{1-4} alkyl.
57. (re-presented - formerly claim 33) A compound according to claim 1 wherein R^2 is H or C_{1-3} alkyl and R^1 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.
58. (re-presented - formerly claim 35) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O- C_{1-4} alkyl.

USSN 10/091,232

OFFICIAL
CT 2666 NP

59. (re-presented - formerly claim 36) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is $N(H)C(O)O-C_{1-4}$ alkyl.
60. (re-presented - formerly claim 37) A compound according to claim 1 wherein R^1 is H or C_{1-3} alkyl and R^2 is C_{3-6} cycloalkyl, phenyl or -O-phenyl.
61. (re-presented - formerly claim 43) A method of treating depression, anxiety disorders, premature ejaculation, urinary incontinence, chronic pain, obsessive-compulsive disorder, feeding disorders, premenstrual dysphoric disorder, hot flashes, panic disorders, posttraumatic stress disorder or social phobia comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
62. (re-presented - formerly claim 44) A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
63. (re-presented - formerly claim 47) A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and an erectile dysfunction agent.
64. (re-presented - formerly claim 48) A method of treating sexual dysfunction in a mammal in need thereof comprising the administration of a pharmaceutically acceptable salt or solvate of a compound according to claim 1 and sildenafil.
65. (new) A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.